Sequencing is specific to patients.

Poh says there is no single algorithm that applies to the treatment for patients with relapse or refractory follicular lymphoma. One of the main distinctions, however, is between early relapse and a late relapse, she observes. If a patient progresses within 24 months of their initial treatment, that's generally considered high-risk disease, and a treatment strategy that can provide a deeper and more durable response for patients will get consideration. Beyond second-line treatment, the treatment landscape becomes broader, she notes, and depending on the patient’s prior therapies and fitness, it includes bispecific antibodies given as monotherapy and chimeric antigen receptor T cell therapy.